Pituitary Tumors Clinical Trial
Official title:
A Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors
NCT number | NCT01689727 |
Other study ID # | EC20.7 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | September 2002 |
Verified date | September 2012 |
Source | Endocyte |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Many types of cancers overexpress a receptor for the vitamin folate (Folate Receptor). This Phase 2 study will utilize a standard imaging radionuclide, technetium-99m, conjugated to a ligand (EC20) designed to bind to the folate receptor. The study is designed as an open-label, baseline-controlled study.
Status | Completed |
Enrollment | 40 |
Est. completion date | |
Est. primary completion date | September 2004 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Subjects must meet the following eligibility requirements to be enrolled in the study: 1. Subject must be 18 years of age or older. 2. Subject must have a pituitary tumor. 3. Subject must have good kidney function. 3. Subject must provide written informed consent prior to enrollment. Exclusion Criteria: Subjects must be excluded if any of the following conditions are present: 1. Subject is pregnant or breastfeeding. 2. Subject is simultaneously participating in another investigational drug study. 3. Subject has completed the follow-up phase of any previous study loess than 30 days prior to enrollment in this study. 4. Subject is unable to tolerate conditions for radionuclide imaging. 5. Subject has been administered another radiopharmaceutical that would interfere with the assessment of Technetium Tc 99m EC20. |
Country | Name | City | State |
---|---|---|---|
United States | Emory Hospital | Atlanta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Endocyte |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01903967 -
Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH)
|
N/A | |
Completed |
NCT01322945 -
Barrow Nasal Inventory Survey
|
N/A | |
Completed |
NCT00565903 -
Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome
|
||
Completed |
NCT01794793 -
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
|
Phase 4 | |
Completed |
NCT00462475 -
Effect of 5 Years of GH Replacement on Atherosclerosis
|
Phase 4 | |
Recruiting |
NCT05634655 -
Dissecting the Mechanism of DNA Methylation on the Invasiveness of Pituitary Tumors.
|